Lorlatinib Continuation Study
← catalyst calendarNCT05144997 · readout in 131 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
76actual
Sites
27
Countries
China, France, India +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-28 | actual | When the study began enrolling |
| Primary completion | 2026-12-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-28 | estimated | The whole study's end, after follow-up |
| First posted | 2021-12-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-Small-Cell Lung Cancer
- NSCLC
Intervention
- Drug: Lorlatinib — also filed as PF-06463922
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events leading to permanent discontinuation of study intervention
measured Baseline up to approximately 5 years
Number of serious adverse events reported for all participants
measured Baseline up to approximately 5 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed